We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.52B
AUM Growth
+$387M
Cap. Flow
+$63.5M
Cap. Flow %
2.52%
Top 10 Hldgs %
45.8%
Holding
129
New
32
Increased
30
Reduced
16
Closed
13

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$33.4M
2
ABBV icon
AbbVie
ABBV
+$31.2M
3
AGN
Allergan plc
AGN
+$24M
4
BAX icon
Baxter International
BAX
+$22.3M
5
GILD icon
Gilead Sciences
GILD
+$20.2M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$59.8M
2
AGN
Allergan Inc
AGN
+$48.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.5M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$22.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.47%
2 Miscellaneous 11.07%
3 Real Estate 3.95%
4 Financials 1.4%
5 Industrials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$230M 9.11%
1,994,834
– –
GILD icon
2
Gilead Sciences
GILD
$181B
$224M 8.86%
2,279,731
+199,000
+10% +$20.2M
BIIB icon
3
Biogen
BIIB
$31.9B
$143M 5.68%
339,483
+12,200
+4% +$4.81M
AGN
4
DELISTED
Allergan plc
AGN
$108M 4.27%
361,686
+84,055
+30% +$24M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$87M 3.45%
502,305
+25,200
+5% +$4.56M
INCY icon
6
Incyte
INCY
$24.7B
$85.8M 3.4%
936,461
– –
REGN icon
7
Regeneron Pharmaceuticals
REGN
$79.7B
$84.5M 3.35%
187,166
-11,200
-6% -$4.75M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12.5B
$66.7M 2.64%
534,977
-35,050
-6% -$3.71M
ABBV icon
9
AbbVie
ABBV
$465B
$65M 2.58%
1,110,614
+516,395
+87% +$31.2M
TEVA icon
10
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$62.1M 2.46%
997,594
+574,000
+136% +$33.4M
VTRS icon
11
Viatris
VTRS
$19.1B
$60M 2.38%
1,010,105
– –
PFE icon
12
Pfizer
PFE
$157B
$57M 2.26%
1,726,706
– –
AMGN icon
13
Amgen
AMGN
$203B
$56.2M 2.23%
351,779
-28,500
-7% -$4.49M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$130B
$54.8M 2.17%
464,244
-237,700
-34% -$28.5M
JNJ icon
15
Johnson & Johnson
JNJ
$644B
$43.7M 1.73%
434,612
+107,400
+33% +$10.9M
GILD icon
16
CALL
Gilead Sciences
GILD
$181B
$42.2M 1.67%
430,100
+429,139
+44,655% +$43.6M
AKRX
17
DELISTED
Akorn Inc
AKRX
$40.4M 1.6%
849,482
– –
ALKS icon
18
Alkermes
ALKS
$7.72B
$35.9M 1.42%
588,470
+151,500
+35% +$10.4M
AET
19
DELISTED
Aetna Inc
AET
$35.4M 1.4%
331,931
– –
BMY icon
20
Bristol-Myers Squibb
BMY
$130B
$34.5M 1.37%
535,240
– –
CTRX
21
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$25.8M 1.02%
433,600
– –
ILMN icon
22
Illumina
ILMN
$33.6B
$24.7M 0.98%
136,972
+30,223
+28% +$5.69M
MOH icon
23
Molina Healthcare
MOH
$10.8B
$23.4M 0.93%
347,901
– –
ACOR
24
DELISTED
Acorda Therapeutics
ACOR
$22.7M 0.9%
5,674
+3,398
+149% +$15.6M
ENDP
25
DELISTED
Endo International plc
ENDP
$22.6M 0.89%
251,773
– –
1
2 3 4 5

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Tekla Capital Management held 129 positions worth $2.52B, up 18% from $2.14B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Tekla Capital Management's Q1 2015 filing shows 32 new, 30 increased, 16 reduced and 13 closed positions. Its largest new stake was Baxter International: 588,384 shares worth $21.9M. The largest sale was Shire pic, an estimated $59.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Real Estate.

  • Tekla Capital Management's largest Q1 2015 buy was Baxter International: 588,384 shares worth $21.9M.
  • Tekla Capital Management added most to Teva Pharmaceutical Industries Limited in Q1 2015, an estimated $33.4M increase.
  • Tekla Capital Management's biggest Q1 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $28.5M.
  • Tekla Capital Management fully exited Shire pic in Q1 2015, selling an estimated $59.8M.
  • Tekla Capital Management's ten largest holdings make up 46% of its $2.52B portfolio in Q1 2015.
  • Tekla Capital Management opened 32 new positions and closed 13 in Q1 2015.
  • Tekla Capital Management's portfolio value rose 18% quarter-over-quarter to $2.52B.

Based on Tekla Capital Management's 13F filing for Q1 2015, filed 6 May 2015.